Prolific: revolutionising the way the world learns about people
Pioneering a future of informed decisions: how Prolific is shaping the next wave of research and AI training with human-centric, quality data across the globe.
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
Pioneering a future of informed decisions: how Prolific is shaping the next wave of research and AI training with human-centric, quality data across the globe.
For the latest in our CEO Spotlight series, we caught up with Dr Tony Coombs, Executive Chairman of Oxford VacMedix - a spinout company making waves in the world of cancer vaccines with its impressive pre-clinical and Phase 1 trial results.
The second year of the Jamies Awards deliver ideas that tackle plastic waste, drug discovery, and bad coffee.
From supermarket peas to multi million-dollar deals: Oxford's biotech startups are rewriting the playbook on chronic inflammation, genomic mysteries, and the AI in medicine. Witness how audacious ideas, nurtured in humble settings, mature into world-changing medical innovations in an ecosystem where science, business, and global impact entwine.
Funding via the Connecting Capability Fund will provide acceleration of support for the UK university social venture sector.
Caristo's Frank Cheng speaks with OUI on transforming heart disease diagnostics, the evolution of Oxford, and the future of one of Oxford's most exciting companies.
Beacon Therapeutics, a pioneering new biotech company, has launched with a mission to restore and improve the vision of patients with retinal diseases. The company is one of the most ambitious spinouts the University has been involved in to date, starting out with an impressive £96 million ($118.5m) in funding, the biggest launch for any company including an Oxford spin-out programme.
Take a glimpse into the future with startups emerging from OUI’s incubator.